CN104640880B - Kir3dl2结合剂 - Google Patents

Kir3dl2结合剂 Download PDF

Info

Publication number
CN104640880B
CN104640880B CN201380048468.1A CN201380048468A CN104640880B CN 104640880 B CN104640880 B CN 104640880B CN 201380048468 A CN201380048468 A CN 201380048468A CN 104640880 B CN104640880 B CN 104640880B
Authority
CN
China
Prior art keywords
antibody
kir3dl2
cells
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380048468.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104640880A (zh
Inventor
L·高蒂尔
S·康陇伯杰
B·罗西
H·西卡德
C·帕图雷
S·科纳
S·泽比布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN104640880A publication Critical patent/CN104640880A/zh
Application granted granted Critical
Publication of CN104640880B publication Critical patent/CN104640880B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
CN201380048468.1A 2012-09-19 2013-09-17 Kir3dl2结合剂 Active CN104640880B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702834P 2012-09-19 2012-09-19
US61/702,834 2012-09-19
PCT/EP2013/069302 WO2014044686A1 (en) 2012-09-19 2013-09-17 Kir3dl2 binding agents

Publications (2)

Publication Number Publication Date
CN104640880A CN104640880A (zh) 2015-05-20
CN104640880B true CN104640880B (zh) 2020-06-09

Family

ID=49226157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380048468.1A Active CN104640880B (zh) 2012-09-19 2013-09-17 Kir3dl2结合剂

Country Status (13)

Country Link
US (3) US10577419B2 (enExample)
EP (1) EP2897980B1 (enExample)
JP (1) JP6507097B2 (enExample)
CN (1) CN104640880B (enExample)
AU (1) AU2013320360B2 (enExample)
BR (1) BR112015006060B1 (enExample)
CA (1) CA2881765C (enExample)
DK (1) DK2897980T3 (enExample)
ES (1) ES2770399T3 (enExample)
IL (1) IL237220B (enExample)
MX (1) MX369148B (enExample)
RU (1) RU2682449C2 (enExample)
WO (1) WO2014044686A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379598B1 (en) * 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
CA2881765C (en) 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
ES2878749T3 (es) * 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
US10519234B2 (en) 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
DK3160994T3 (da) 2014-06-27 2025-05-05 Innate Pharma Multispecifikke antigenbindende proteiner
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
WO2016199097A1 (en) * 2015-06-10 2016-12-15 National Research Council Of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
CA2990518A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
US20200048345A1 (en) 2015-12-28 2020-02-13 Innate Pharma Multispecific antigen binding proteins
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
KR20190068602A (ko) 2016-10-21 2019-06-18 이나뜨 파르마 항-kir3dl2 작용제에 의한 치료
US20190322767A1 (en) 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins
EP3579879A4 (en) * 2017-02-09 2020-12-16 Memorial Sloan Kettering Cancer Center ANTI-BODY ANTI-KIR3DL1
CA3064443A1 (en) * 2017-05-24 2018-11-29 Development Center For Biotechnology Humanized antibodies against globo h and uses thereof in cancer treatments
US10947316B2 (en) * 2017-06-15 2021-03-16 Development Center For Biotechnology Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
BR112021014236A2 (pt) 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia
CN110950960B (zh) * 2019-11-26 2021-05-14 中国农业大学 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法
CA3172697A1 (en) * 2020-03-23 2021-09-30 Ruth Yin-Zong LAN Anti-ccr8 antibodies for treating cancer
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
US20240199750A1 (en) 2021-03-26 2024-06-20 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022214432A1 (en) 2021-04-05 2022-10-13 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
EP4351733A1 (en) 2021-06-09 2024-04-17 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
KR20240019297A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
KR20240040098A (ko) * 2021-07-30 2024-03-27 알.피.쉐러 테크놀러지즈 엘엘씨 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
JP2025532464A (ja) 2022-09-15 2025-10-01 アビディキュア アイピー ビー．ブイ． Ｎｋ細胞の腫瘍標的化のための多重特異性抗原結合タンパク質及びその使用
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050122A2 (en) * 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
WO2010081890A1 (en) * 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060079180A (ko) * 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2012047294A2 (en) * 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
CA2881765C (en) 2012-09-19 2024-02-13 Innate Pharma Kir3dl2 binding agents
EP2897979B1 (en) * 2012-09-19 2019-02-13 Innate Pharma Kir3dl2 binding agents
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
KR20190068602A (ko) 2016-10-21 2019-06-18 이나뜨 파르마 항-kir3dl2 작용제에 의한 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050122A2 (en) * 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
WO2010081890A1 (en) * 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Les lymphomes T épidermotropes comme modèles de progression tumorale;MARTINE BAGOT ET AL;《DECINE/SCIENCES》;20060228;第22卷(第2期);192-196 *
Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104;BRANDO CLARA ET AL;《JOURNAL OF LEUKOCYTE BIOLOGY》;359-371;20050831;第78卷(第2期);359-371 *
THE NATURAL KILLER CELL RECEPTOR SPECIFIC FOR HLA-A ALLOTYPES: A NOVEL MEMBER OF THE P58/P70 FAMILY OF INHIBITORY RECEPTORS THAT IS CHARACTERIZED BY THREE IMMUNOGLOBULIN-LIKE DOMAINS AND IS EXPRESSED AS A 140-KD DISULPHIDE-LINKED DIMER;PENDE D ET AL;《THE JOURNAL OF EXPERIMENTAL MEDICINE》;19960801;第184卷(第2期);505-518 *

Also Published As

Publication number Publication date
MX369148B (es) 2019-10-30
DK2897980T3 (da) 2020-02-17
AU2013320360A1 (en) 2015-03-05
IL237220B (en) 2020-02-27
EP2897980A1 (en) 2015-07-29
RU2682449C2 (ru) 2019-03-19
JP6507097B2 (ja) 2019-04-24
US20240124579A1 (en) 2024-04-18
RU2015104760A (ru) 2016-11-10
CA2881765C (en) 2024-02-13
BR112015006060A2 (pt) 2018-09-25
WO2014044686A1 (en) 2014-03-27
US20150232556A1 (en) 2015-08-20
AU2013320360B2 (en) 2018-06-14
US20200199228A1 (en) 2020-06-25
CA2881765A1 (en) 2014-03-27
ES2770399T3 (es) 2020-07-01
BR112015006060B1 (pt) 2023-03-21
EP2897980B1 (en) 2019-11-06
JP2015535820A (ja) 2015-12-17
US10577419B2 (en) 2020-03-03
MX2015003476A (es) 2015-08-10
US11858990B2 (en) 2024-01-02
IL237220A0 (en) 2015-04-30
CN104640880A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
US20240124579A1 (en) Kir3dl2 binding agents
US20200299380A1 (en) Mica binding agents
EP2958941B1 (en) A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
US20170267764A1 (en) Anti-mica antibodies
KR102345173B1 (ko) 증가된 안정성을 가진 인간화 항체
TW202204415A (zh) FcRH5之人源化及親和力成熟抗體及使用方法
JP2021509822A (ja) 抗ｍｃｔ１抗体およびその使用
US20240391999A1 (en) Treatment with anti-kir3dl2 agents
HK1229358B (zh) 具有增加的稳定性的人源化抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant